Stockwatch: Difficult decisions
This article was originally published in Scrip
Executive Summary
Whilst everyone who's anyone in biotechnology schmoozed along to BIO conference in Boston 18-21 June 2012, regulators on both sides of the Atlantic were grappling with difficult decisions – those that expose the tension between patient access to a new drug, and the drug's safety.